Lymphedema associated genes and model
    1.
    发明申请
    Lymphedema associated genes and model 有权
    淋巴水肿相关基因和模型

    公开(公告)号:US20120076731A1

    公开(公告)日:2012-03-29

    申请号:US13136372

    申请日:2011-07-28

    摘要: The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

    摘要翻译: 本发明鉴定了淋巴水肿组织中基因产物差异表达的基因,特别是涉及淋巴水肿全器官反应的皮肤组织。 本发明提供诊断或评估个体对淋巴水肿易感性的方法。 还提供了治疗患者的治疗方法或用于预防性治疗易患淋巴水肿的个体的方法。 此外,本发明描述了用于鉴定可以施用以治疗患有或有发展为淋巴水肿风险的个体的药剂的筛选方法。

    TWO BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    4.
    发明申请
    TWO BIOMARKERS FOR DIAGNOSIS AND MONITORING OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE 审中-公开
    两个生物标记物用于诊断和监测甲状旁腺性心脏病

    公开(公告)号:US20080300797A1

    公开(公告)日:2008-12-04

    申请号:US11963673

    申请日:2007-12-21

    IPC分类号: G01N33/48

    摘要: The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

    摘要翻译: 本发明鉴定了新鉴定为在动脉粥样硬化中差异表达的两种循环蛋白。 这两种蛋白质的循环水平,特别是作为一组蛋白质,可以将患有急性心肌梗死的患者与具有稳定的劳力性心绞痛的患者以及没有动脉粥样硬化性心血管疾病史的患者区分开来。 这些水平也可以预测心血管事件,确定治疗的有效性,疾病阶段等。 例如,这些标记物可用作开发血管特异性药剂所需的临床事件的替代生物标志物。

    Cardiac pressure overload associated genes
    5.
    发明申请
    Cardiac pressure overload associated genes 审中-公开
    心脏压力过载相关基因

    公开(公告)号:US20060094038A1

    公开(公告)日:2006-05-04

    申请号:US11231700

    申请日:2005-09-20

    IPC分类号: C12Q1/68 G01N33/53 C12M1/34

    摘要: The present invention identifies genes whose gene products are differentially expressed pressure overload of the heart. The invention provides methods for diagnosing or assessing an individual's susceptibility to heart failure from many etiologies, as well as the presence and severity of hypertrophy, chamber enlargement, or systolic heat failure. Also provided are therapeutic methods for treating a heart patient or methods for prophylactically treating an individual susceptible to heart failure. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered a heart attack or are at risk of heart failure.

    摘要翻译: 本发明鉴定出基因产物差异表达心脏压力超负荷的基因。 本发明提供了用于诊断或评估个体对许多病因的心力衰竭易感性的方法,以及肥大,室扩大或收缩热衰竭的存在和严重性。 还提供了治疗心脏病患者的治疗方法或用于预防性治疗易患心力衰竭的个体的方法。 另外,本发明描述了用于鉴定可以施用以治疗已经患有心脏病发作或处于心力衰竭风险的个体的药剂的筛选方法。

    Method for the treatment of acquired lymphedema
    6.
    发明授权
    Method for the treatment of acquired lymphedema 有权
    治疗获得性淋巴水肿的方法

    公开(公告)号:US08965708B2

    公开(公告)日:2015-02-24

    申请号:US13136372

    申请日:2011-07-28

    IPC分类号: G01N33/48 A61B5/00 C12Q1/68

    摘要: The present invention identifies genes whose gene products are differentially expressed in lymphedema tissues, particularly cutaneous tissue involved in whole organ response to lymphedema. The invention provides methods for diagnosing or assessing an individual's susceptibility to lymphedema. Also provided are therapeutic methods for treating a patient or methods for prophylactically treating an individual susceptible to lymphedema. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have or at risk of developing lymphedema.

    摘要翻译: 本发明鉴定了淋巴水肿组织中基因产物差异表达的基因,特别是涉及淋巴水肿全器官反应的皮肤组织。 本发明提供诊断或评估个体对淋巴水肿易感性的方法。 还提供了治疗患者的治疗方法或用于预防性治疗易患淋巴水肿的个体的方法。 此外,本发明描述了用于鉴定可以施用以治疗患有或有发展为淋巴水肿风险的个体的药剂的筛选方法。

    Atherosclerosis genes and related reagents and methods of use thereof
    7.
    发明申请
    Atherosclerosis genes and related reagents and methods of use thereof 审中-公开
    动脉粥样硬化基因及相关试剂及其使用方法

    公开(公告)号:US20070253901A1

    公开(公告)日:2007-11-01

    申请号:US11412437

    申请日:2006-04-27

    CPC分类号: G01N33/6893 G01N2800/323

    摘要: The invention provides genes (DEA genes) that are differentially expressed in atherosclerotic lesions and polypeptides encoded by these genes. The invention provides compositions comprising a targeting agent conjugated to a functional moiety, wherein the targeting agent selectively binds to a polypeptide encoded by one a DEA gene. The functional moiety can be an imaging agent, therapeutic agent, etc. The invention further provides methods for providing diagnostic or prognostic information related to atherosclerosis involving detecting expression or activity of an expression product of one or more of the DEA genes. The invention further provides therapeutic methods comprising administering to a subject a composition comprising a targeting agent conjugated to a functional moiety that binds selectively binds to a polypeptide encoded by a DEA gene.

    摘要翻译: 本发明提供在动脉粥样硬化病变和由这些基因编码的多肽中差异表达的基因(DEA基因)。 本发明提供了包含与功能部分缀合的靶向剂的组合物,其中所述靶向剂选择性地结合由DEA基因之一编码的多肽。 功能部分可以是显像剂,治疗剂等。本发明还提供了提供涉及检测一种或多种DEA基因的表达产物的表达或活性的动脉粥样硬化相关的诊断或预后信息的方法。 本发明进一步提供治疗方法,包括向受试者施用包含与功能性部分缀合的靶向试剂的组合物,其结合选择性结合由DEA基因编码的多肽。

    Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease
    8.
    发明申请
    Methods and compositions for diagnosis, monitoring and development of therapeutics for treatment of atherosclerotic disease 审中-公开
    用于诊断,监测和开发用于治疗动脉粥样硬化疾病的治疗剂的方法和组合物

    公开(公告)号:US20070092886A1

    公开(公告)日:2007-04-26

    申请号:US11387484

    申请日:2006-03-22

    IPC分类号: C12Q1/68 C12M3/00

    摘要: Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and/or to identify compounds effective to treat an atherosclerotic disease condition.

    摘要翻译: 提供了与动脉粥样硬化疾病病症中差异表达的基因相对应的多核苷酸序列。 还提供了使用这些序列来检测哺乳动物的基因表达和/或转录谱的方法。 本发明的多核苷酸序列可用于诊断动脉粥样硬化疾病,监测治疗进展程度或疗效或评估动脉粥样硬化疾病的预后,和/或鉴定有效治疗动脉粥样硬化疾病病症的化合物。

    METHODS AND COMPOSITIONS FOR DIAGNOSIS, MONITORING AND DEVELOPMENT OF THERAPEUTICS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE
    10.
    发明申请
    METHODS AND COMPOSITIONS FOR DIAGNOSIS, MONITORING AND DEVELOPMENT OF THERAPEUTICS FOR TREATMENT OF ATHEROSCLEROTIC DISEASE 审中-公开
    用于治疗甲状腺疾病的治疗药物的诊断,监测和开发的方法和组合

    公开(公告)号:US20090305903A1

    公开(公告)日:2009-12-10

    申请号:US12205618

    申请日:2008-09-05

    IPC分类号: C40B30/04 C12Q1/68 C40B40/08

    摘要: Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and/or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and/or to identify compounds effective to treat an atherosclerotic disease condition.

    摘要翻译: 提供了与动脉粥样硬化疾病病症中差异表达的基因相对应的多核苷酸序列。 还提供了使用这些序列来检测哺乳动物的基因表达和/或转录谱的方法。 本发明的多核苷酸序列可用于诊断动脉粥样硬化疾病,监测治疗进展程度或疗效或评估动脉粥样硬化疾病的预后,和/或鉴定有效治疗动脉粥样硬化疾病病症的化合物。